fda statement bpc-157 not approved fda.gov The FDA's Pharmacy Compounding Advisory Committee is scheduled to meet Thursday and Friday to review some of the controversial, popular peptide injections and discuss whether compounding pharmacies should be able to dispense FDA Puts BPC-157, TB-500, and

Kennedy, who has said he used peptides with "really good effect," has argued that restrictions on the compounds have pushed consumers toward an unregulated grey market

Human pilot evidence Three small pilots: a 12-patient knee-pain case series (Lee & Padgett, Alternative Therapies in Health and Medicine, 2021)

Research suggests it can promote the reorganization of F-actin in fibroblasts, enhancing their structural integrity and migratory capacity

The committee members who voted yes generally believed the risks to be minimal, while those who voted no tended to worry about safety risks and effectiveness, and expressed concern that adding the peptide to the compounding list would create a false impression that it has been evaluated with the same rigorous standards as an FDA-approved drug

Because both peptides promote angiogenesis (new blood vessel growth), they are strictly contraindicated for anyone with an active malignancy or a history of cancer

10.2147/DDDT.S284163 79 XuC.SunL.RenF.HuangP.TianZ.CuiJ.et al (2020)